The very first study of the Corona Virus vaccine began in Iran this week, dozens of people are due to receive the vaccine , which is developed and produced domestically. This is the first time a vaccine has reached the human trails stage in the country. The vaccine is produced by Shifa Pharmed, a State owned pharmaceutical Company called Barekat, the Company explained that the vaccine contains antibiotics.
Iran are currently struggling with the virus, with over 1.2 million infected people and nearly 55,000 killed by the virus. The phase one of the vaccine trail will see 56 volunteers receive two shots of the vaccines within two weeks, results are to be announced a month after the second shot.
It expected the vaccine will hit the market by late 2021, with government accelerating the development of the vaccines nationwide. President Hassan Rouhani said Iran is collaborating with other Countries to produce another vaccine before February, 2021.
Content created and supplied by: Nsikakeyo01 (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More